STOCK TITAN

Histogen Inc - HSTO STOCK NEWS

Welcome to our dedicated news page for Histogen (Ticker: HSTO), a resource for investors and traders seeking the latest updates and insights on Histogen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Histogen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Histogen's position in the market.

Rhea-AI Summary
Histogen Inc. (HSTO) has filed for voluntary Chapter 11 protection to wind down operations and maximize shareholder value. The company plans to distribute all value to stakeholders, including shareholders, after discontinuing further development in September 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Histogen Inc. (OTC: HSTO) has announced the adjournment of its special meeting of stockholders to January 4, 2024. The estimated cash distribution to shareholders is in the range of $0.30 to $0.41 per share of common stock, subject to available cash. The company urges stockholders to vote 'FOR' the Dissolution Proposal and the Adjournment Proposal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
none
-
Rhea-AI Summary
Histogen Inc. (OTC: HSTO) has adjourned its special meeting of stockholders to December 14, 2023. The meeting will continue to be held via live webcast. The company will continue to solicit votes from its stockholders with respect to both proposals set forth in the Proxy Statement. The Histogen Board of Directors unanimously recommends that stockholders vote 'FOR' the Dissolution Proposal and 'FOR' the Adjournment Proposal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.11%
Tags
none
Rhea-AI Summary
Histogen Inc. announces Plan of Dissolution, discontinues clinical development programs, and reduces workforce.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.48%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.97%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
54.65%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
none
Histogen Inc

OTC:HSTO

HSTO Rankings

HSTO Stock Data

2.14M
3.93M
2.85%
5.25%
1.57%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About HSTO

a regenerative medicine company based on naturally-produced products from newborn fibroblasts grown in a proprietary bioreactor. two product families - a proprietary liquid complex of embryonic-like proteins and growth factors, and a human extracellular matrix (ecm) material, exceltrix.